Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Gene Therapy On Neurological Diseases Market CAGR Outlook And Future Development
The gene therapy on neurological diseases market size has experienced swift expansion in recent years. It is projected to increase from $3.55 billion in 2025 to $4.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.0%. The market’s past growth can be attributed to elements such as the scarcity of gene therapy alternatives for neurological conditions, the rising occurrence of Alzheimer’s and Parkinson’s disease, a dependence on traditional treatment methods, growing recognition of genetic methodologies, and the initial clinical testing of viral vectors.
The market size for gene therapy on neurological diseases is anticipated to experience substantial expansion in the coming years. It is projected to grow to $6.48 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 12.7%. This growth over the forecast period can be attributed to the advancement of adeno-associated virus and lentiviral therapies, the broadening of non-viral delivery platforms, a rise in regulatory approvals for neurological gene therapies, increased investment in research and development for targeted genetic interventions, and the incorporation of digital monitoring and AI-based patient management. Significant trends during the forecast period involve heightened investment in viral and non-viral gene therapy platforms, the expanding application of gene therapy across various neurological disorders, a growing emphasis on personalized and targeted genetic treatments, an increase in hospital and clinic-based gene therapy initiatives, and the creation of advanced delivery methods for neurological gene therapy.
Get A Free Sample Report With In-Depth Market Insights:
Gene Therapy On Neurological Diseases Market Industry Drivers: What’s Behind The Revenue Growth?
The expanding occurrence of neurological conditions is projected to boost the gene therapy on neurological diseases market moving forward. These disorders are health conditions impacting the brain, spinal cord, and nerves, resulting in various symptoms like cognitive, motor, and sensory difficulties. Their rising frequency is associated with an aging demographic, given that aging progressively harms neuronal function, diminishes brain plasticity, and heightens oxidative stress, thus aiding in the onset and advancement of these conditions. Gene therapy on neurological diseases assists in managing neurological disorders by addressing their underlying genetic origins, providing potential enduring or permanent treatment options. This therapy enhances patient results through restoring or altering gene function, alleviating symptoms, and lessening the requirement for repeated medical procedures, consequently improving overall quality of life. For example, data from the National Health Service, a UK government body, indicated that by June 30, 2024, 487,432 patients had been diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) in July 2024, marking an increase of 3,155 cases from May 31, 2024. Consequently, the growing incidence of neurological disorders is fueling the expansion of the gene therapy on neurological diseases market.
Gene Therapy On Neurological Diseases Market Segment Landscape: Which Areas Lead Development?
The gene therapy on neurological diseases market covered in this report is segmented –
1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy
2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis
3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus
2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)
#Gene Therapy On Neurological Diseases Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the gene therapy on neurological diseases market are prioritizing the development of advanced viral delivery systems, such as the adeno-associated virus serotype 2 (AAV2) vector. Their aim is to enhance targeted gene delivery, increase efficacy, lessen immune reactions, and enable prolonged treatments. The adeno-associated virus serotype 2 (AAV2) vector is a modified, non-pathogenic viral delivery system employed in gene therapy to transport therapeutic genes into specific cells, especially neurons, for sustained expression. As an illustration, in November 2024, PTC Therapeutics Inc., a biopharmaceutical company located in the US, obtained U.S. Food and Drug Administration (FDA) approval for a gene therapy designed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy utilizes an AAV2 vector to deliver a functional copy of the DDC gene into the putamen, which facilitates dopamine production and improves motor functions. It is characterized by a single, intraputaminal infusion engineered to provide sustained therapeutic benefits, leading to significant improvements in motor function and a reduction in debilitating symptoms without the necessity for repeated interventions.
Gene Therapy On Neurological Diseases Market Industry Leaders And Competitive Landscape
Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG
View The Full Gene Therapy On Neurological Diseases Market Report:
Gene Therapy On Neurological Diseases Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model